CureVac disclosed that its COVID-19 vaccine has an efficacy of 48 percent against fifteen COVID-19 variants.
Further, the company said that the CureVac vaccination performed slightly better for younger volunteers: effectiveness improved to 53 percent for those aged 18 to 60. According to the researchers, the vaccine also gave 100 percent protection against hospitalization and death in that group.
According to Reuters and The New York Times, in clinical studies, the Moderna and Pfizer-BioNTech vaccines, which use the same mRNA technology as CureVac, achieved effectiveness rates of around 95 percent. According to Franz-Werner Haas, CureVac's CEO, the European Medicines Agency began a rolling study of CureVac's vaccine in February 2021. The corporation stated that it would continue to submit those documents. Vaccinations are critical in combating the COVID-19 pandemic and the proliferation of dynamic variants.